Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression- and treatment-free following a single...
-- Bezuclastinib achieves clear clinical benefit across all symptom domains including significant improvements on 11 individual symptoms plus the most...
Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a study with median progression...
Media ReleaseCOPENHAGEN, Denmark; December 6, 2025 New two- and three-year EPCORE® NHL-2 follow-up data evaluating epcoritamab in combination with standard...
VANCOUVER, BC / ACCESS Newswire / December 7, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company")...
New multilingual capabilities expand access to real-time GLP-1 dining guidance as WHO highlights the importance of protein-focused nutrition.BOSTON, Dec. 6,...
ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation (OTC:HIRU) ("Ameerex" or the "Company"),...
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to...
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial to evaluate ARV-393 plus glofitamab...
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical company headquartered in Spring, Texas;...
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety profile comparable to 1500mg QW...
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed AML patients with diverse mutationsSafety...
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response was seen independent of concomitant...
Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment...
Phase 2 results selected as one of only 10 featured presentations in the Poster Tour at the 2025 Parkinson Study...
Highly differentiated 1L preliminary systemic activity of 67% ORR and 100% intracranial ORR (by BICR-RANO), including in patients with active...
Authorized distribution partnership brings VHF's industry-leading milling technology to Shinoda Dental's global customers. SINGAPORE, SG / ACCESS Newswire / December...
LOS ANGELES, Dec. 5, 2025 /PRNewswire/ -- AI-generated deepfake scams are rapidly spreading across social media, using fabricated videos, synthetic voices,...
Not for distribution to United States newswire services or for dissemination in the United States. VANCOUVER, BC / ACCESS Newswire / December 5, 2025 / Queue Ventures Ltd. ("Queue")...
Not for distribution to United States newswire services or for dissemination in the United States. VANCOUVER, BC / ACCESS Newswire / December 5, 2025 / Queue Ventures Ltd. ("Queue")...